

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ADICON Holdings Limited
艾迪康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9860)

**APPOINTMENT OF EXECUTIVE DIRECTOR
AND
CHANGE IN THE COMPOSITION OF BOARD COMMITTEE**

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of ADICON Holdings Limited (the “**Company**”) is pleased to announce that with effect from February 13, 2026, Mr. WANG Legang (“**Mr. WANG**”) has been appointed as an executive Director of the Company. Mr. WANG has been appointed as the chief operating officer and the general manager of the Group since August 15, 2025 and he will continue to act as the chief operating officer and the general manager of the Group.

The biographical details of Mr. WANG are as follows:

Mr. WANG, aged 45, has extensive experience in healthcare business management and digital transformation. Early in his career, from July 2004 to March 2009, Mr. WANG was a pharmaceutical engineer at Qingdao Huanghai Pharmaceutical Co., Ltd. (青島黃海製藥有限公司). From March 2009 to July 2014, Mr. WANG served as a regional manager and marketing manager at Pfizer (China) Investment Co., Ltd. (輝瑞(中國)投資有限公司). He then served as a regional director responsible for pharmaceutical sales of Merck (China) Investment Co., Ltd. (默沙東(中國)投資有限公司) from July 2014 to March 2018, before becoming a vice president of the Medlinker (成都醫雲科技有限公司), a role he held from March 2018 to February 2021 mainly in charge of the group’s business management and digital pharmaceutical sales networks development. From February 2021 to September 2024, he served as the senior vice president of Cowell Health (高濟健康-瓴創(北京)科技有限公司) and also led the interactive medicine and innovative drug division of the group as a general manager. From April 2025 to August 2025, Mr. WANG served as the deputy general manager of the Jointown Pharmaceutical Group (九州通醫藥集團股份有限公司) and the general manager of Jiuyi Clinic (Hubei) Co., Ltd. (九醫診所(湖北)有限公司).

Mr. WANG obtained a bachelor's degree in clinical pharmacy from Harbin Medical University in the People's Republic of China in June 2004 and finished EMBA courses from Ocean University of China in November 2014.

A service agreement has been entered into between Mr. WANG and the Company for a term of three years commencing from his appointment. Mr. WANG's appointment as an executive Director shall be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Company's articles of association. Mr. WANG is not entitled to any director's fee for his directorship with the Company. The emolument of Mr. WANG is determined by the Board upon recommendation from the remuneration committee of the Board with reference to his qualification, experience, level of duties and responsibilities undertaken in the Company and the prevailing market conditions.

Mr. WANG has obtained the legal advice referred to in Rule 3.09D of the Listing Rules.

To the best knowledge of the Directors, save as disclosed above, as at the date of this announcement, (i) Mr. WANG does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders (having the meaning ascribed to it in the Listing Rules) of the Company; (ii) Mr. WANG does not hold any other position within the Company or other members of the Group; (iii) Mr. WANG does not hold any directorship in any listed public companies which are listed in Hong Kong or overseas in the past three years and other major appointments and professional qualifications; (iv) there is no other information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules, nor are there any other matters that need to be brought to the attention of the shareholders of the Company; and (v) Mr. WANG does not have any interest in or is deemed to be interested in any shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The Board would like to express its warmest welcome to Mr. WANG for joining the Board.

CHANGE IN THE COMPOSITION OF BOARD COMMITTEE

With effect from February 13, 2026, Mr. WANG has been further appointed by the Board as a member of the strategy committee of the Board.

By Order of the Board
ADICON Holdings Limited
Ms. YANG Ling
Chairwoman

Hong Kong, February 13, 2026

As at the date of this announcement, the Board comprises Mr. GAO Song and Mr. WANG Legang as executive Directors; Ms. YANG Ling, Mr. LIN Jixun, Ms. FENG Janine Junyuan and Mr. ZHOU Mintao as non-executive Directors; and Mr. MI Brian Zihou, Mr. YEH Richard and Mr. ZHANG Wei as independent non-executive Directors.